• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 3. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 4. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Phenylpyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Phenylpyrimidines

Recent Advances in the Study of 6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (CAS: 375834-47-2): A Comprehensive Research Brief

6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (CAS: 375834-47-2) is a pyrimidine derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive compounds, particularly those targeting enzyme inhibition and anticancer activity. This research brief aims to summarize the latest findings related to this compound, focusing on its chemical properties, biological activities, and potential applications in drug development.

The compound's structural features, including the hydroxyphenyl and thioxo groups, contribute to its unique reactivity and interaction with biological targets. Recent synthetic approaches have optimized the yield and purity of 6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one, enabling more efficient scale-up for preclinical studies. Advanced spectroscopic techniques, such as NMR and mass spectrometry, have been employed to characterize its molecular structure and confirm its identity, ensuring reproducibility in research applications.

In vitro studies have demonstrated that 6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one exhibits promising inhibitory effects against specific enzymes involved in inflammatory pathways. For instance, recent research published in the Journal of Medicinal Chemistry highlighted its ability to modulate COX-2 activity, suggesting potential applications in the development of anti-inflammatory agents. Additionally, molecular docking simulations have revealed its binding affinity for key residues in the active site of target proteins, providing insights into its mechanism of action.

Beyond its anti-inflammatory properties, this compound has also shown cytotoxic effects against certain cancer cell lines. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of 6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one induced apoptosis in breast cancer cells via the mitochondrial pathway. These findings underscore its potential as a scaffold for designing novel anticancer agents, with ongoing research focusing on structure-activity relationships to enhance potency and selectivity.

Despite these promising results, challenges remain in the clinical translation of 6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one. Pharmacokinetic studies indicate limited bioavailability, prompting investigations into prodrug strategies and formulation optimization. Recent advancements in nanotechnology have explored encapsulation techniques to improve its solubility and delivery, as documented in a 2024 ACS Nano publication. These efforts aim to address the compound's physicochemical limitations while preserving its biological activity.

In conclusion, 6-(4-Hydroxyphenyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (CAS: 375834-47-2) represents a versatile scaffold with significant potential in drug discovery. Its dual role as an enzyme inhibitor and cytotoxic agent highlights its broad applicability in treating inflammatory diseases and cancer. Future research should focus on optimizing its pharmacokinetic profile and exploring synergistic effects with existing therapeutics. As the field advances, this compound may pave the way for the development of next-generation small-molecule drugs with improved efficacy and safety profiles.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)